Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

PURPOSE: This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation–associated breast cancer. PATIENTS AND METHODS: This single-arm phase II study enrolled patients wit...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Telli, Melinda L., Jensen, Kristin C., Vinayak, Shaveta, Kurian, Allison W., Lipson, Jafi A., Flaherty, Patrick J., Timms, Kirsten, Abkevich, Victor, Schackmann, Elizabeth A., Wapnir, Irene L., Carlson, Robert W., Chang, Pei-Jen, Sparano, Joseph A., Head, Bobbie, Goldstein, Lori J., Haley, Barbara, Dakhil, Shaker R., Reid, Julia E., Hartman, Anne-Renee, Manola, Judith, Ford, James M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2015
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451172/
https://ncbi.nlm.nih.gov/pubmed/25847929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0085
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items